After turning its back on an offer from generics competitor Teva, Mylan stepped up with an unsuccessful hostile takeover bid for generic drugmaker Perrigo. Mylan didn’t stop there: A couple of months before President Obama put the regulatory kibosh on tax inversion deals, the company announced intentions to acquire Swedish drug firm Meda AB and its portfolio of respiratory, pain, and inflammation products for $7.2 billion. The new rules will not deter the generic drugmaker’s plans, a Mylan spokesperson told Bloomberg News. All this activity came after Mylan snapped up Abbott Laboratories’ specialty and branded generics business overseas in order to reincorporate in the Netherlands. On the U.S. front, expanded legislation and policies that allow (or require) schools to stock EpiPen, an epinephrine injection to treat anaphylaxis, helped elevate the lifesaving device to blockbuster status. Recent notable launches include generic Epivir (lamivudine) tablets for HIV and hepatitis B and new strengths of generic Lopressor (metoprolol tartrate), Novartis’s hypertension and angina drug.